Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19

Phase 3

Not yet recruiting

• Conditions: COVID
• Interventions: Drug: ACEIs; Drug: Conventional treatment

• Registration Number: NCT04345406
• Lead Sponsor: Tanta University

Brief Summary

ACEIs as treatment for COVID19

Detailed Description

ACEIs as suggested treatment for COVID19

Study Timeline

• Status Verified: 2020-04
• Study First Submitted: 2020-04-11
• Study First Submitted QC: 2020-04-11
• Last Update Submitted: 2020-04-11
• Study First Posted: 2020-04-14
• Last Update Posted: 2020-04-14
• Study Start: 2020-04-15
• Primary Completion: 2029-12-01
• Study Completion: 2029-12-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Patients infected with covid 19

Exclusion Criteria

• allergy or contraindications to the drug

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ACEIs	ACEIs	ACEIs with conventional treatment for COVID19
ACEIs	Conventional treatment	ACEIs with conventional treatment for COVID19
Conventional treatment of COVID19	Conventional treatment	Conventional treatment of COVID19

Primary Outcome Measures

Name	Time	Method
number of patients with virological cure	6 months	number of patients with virological cure

Trial Locations

Locations (1)

Tanta University; 🇪🇬 Tanta, Egypt